The rheumatoid arthritis market size was valued at USD 27.15 billion in 2025 and is projected to grow from USD 28.62 billion in 2026 to USD 44.20 billion by 2034, registering a CAGR of 5.59% during the forecast period (2026–2034). North America dominated the rheumatoid arthritis market with a market share of 51.93% in 2025.
Rheumatoid arthritis is a chronic autoimmune disease characterized by inflammation of the joints, leading to pain, swelling, stiffness, and progressive joint damage. The condition primarily affects the synovial lining of joints but may also involve other organs, causing systemic complications. Rheumatoid arthritis is commonly managed through disease-modifying antirheumatic drugs (DMARDs), biologics, targeted therapies, and supportive care to reduce disease progression, relieve symptoms, and improve patients' quality of life.
The rheumatoid arthritis market demand is increasing due to the rising prevalence of autoimmune disorders, growing awareness of early diagnosis, and expanding adoption of biologic and targeted therapies. Continuous advancements in treatment options, favorable reimbursement policies, increasing healthcare expenditure, and ongoing research for innovative therapeutics are further supporting rheumatoid arthritis market growth.
Download a Free Sample To learn more about this report,
The rheumatoid arthritis market is sensitive to supply chain disruptions because it relies on globally sourced active pharmaceutical ingredients, biologics, specialty excipients, packaging materials, cold chain logistics, and sterile manufacturing components that require strict quality and regulatory compliance. Disruptions in the supply of these critical materials can delay drug manufacturing, distribution, and product availability, affecting timely patient access to biologics, biosimilars, and targeted therapies across global healthcare systems. Pharmaceutical companies are addressing these challenges by diversifying supplier networks, strengthening regional manufacturing capabilities, increasing safety stock levels, and enhancing digital supply chain monitoring to improve resilience. The rheumatoid arthritis market experienced an S-shaped supply chain recovery, with biologics production, cold chain distribution, and healthcare services gradually normalizing before accelerating as routine patient care and treatment initiation returned to pre-disruption levels.
A key trend in the rheumatoid arthritis market is the integration of ultrasound-guided synovial tissue biopsy with molecular profiling to identify inflammatory endotypes before selecting biologics or targeted therapies. This approach aims to replace empirical drug switching with tissue-based precision treatment. In 2025, multi-omics synovial biomarker research accelerated across leading academic centers, supporting personalized therapeutic decision-making and improving prediction of treatment response in refractory rheumatoid arthritis patients.
A key trend in the rheumatoid arthritis market is the integration of artificial intelligence platforms that predict disease flares using longitudinal electronic health records, wearable sensor data, and patient-reported outcomes. These predictive systems enable proactive treatment adjustments before clinical deterioration occurs, supporting personalized disease management. In 2025, several academic health systems and digital health developers expanded AI-driven rheumatoid arthritis monitoring programs, reflecting growing adoption of predictive analytics within routine rheumatology practice.
The rheumatoid arthritis market forecasts continued investment activity driven by increasing demand for advanced immunology therapies, expansion of precision medicine approaches, and growing commercialization of novel treatment technologies. Investors are focusing on companies developing next-generation biologics, targeted immunomodulators, and innovative non-pharmacological therapies that improve long-term disease management and clinical outcomes.
In 2025, SetPoint Medical raised USD 140 million in private financing, comprising a USD 115 million Series D round and a USD 25 million Series C extension, to commercialize its FDA-approved neuroimmune modulation therapy for moderate-to-severe rheumatoid arthritis, expand manufacturing capacity, strengthen commercial operations, and advance additional autoimmune disease programs. In the same year, UCB announced a planned USD 5 billion capital investment through 2030 to expand biologics manufacturing, enhance research infrastructure, and accelerate immunology innovation. The investment supports the long-term development, production, and global supply of therapies for rheumatoid arthritis and other autoimmune diseases.
Growth of Precision Immunology and Expansion of Advanced Immunology Clinical Pipeline Drives Market
The increasing adoption of precision medicine and treat-to-target strategies is accelerating demand for advanced rheumatoid arthritis therapies. Healthcare providers are increasingly utilizing biomarkers, disease activity monitoring, and individualized treatment pathways to initiate effective disease-modifying therapies earlier, improving remission rates and reducing irreversible joint damage. In March 2026, the 2025 EULAR recommendations reinforced immediate initiation of DMARDs following diagnosis, emphasized sustained treat-to-target monitoring, and simplified treatment sequencing, further encouraging broader adoption of biologics and targeted synthetic DMARDs across routine clinical practice. These updated recommendations are expected to accelerate the uptake of innovative therapies, thereby driving rheumatoid arthritis market growth.
The expanding late-stage immunology pipeline is driving the rheumatoid arthritis market by introducing novel therapies for patients with inadequate response to existing treatments. Since September 2025, multiple Phase II and Phase III candidates, including AstraZeneca's AZD1163 and AZD6912, Eli Lilly's ocadusertib, Rise Therapeutics' R-2487, and TNF Pharmaceuticals' MYMD-1, have advanced in clinical development. This robust pipeline is accelerating innovation, broadening future treatment options, and strengthening long-term market growth.
High Immunogenicity Testing and Mandatory Long-term Safety Monitoring Restrain Market Expansion
Biologic therapies may induce anti-drug antibodies that reduce therapeutic response, requiring immunogenicity testing, therapeutic drug monitoring, and treatment switching. Frequent transitions between originator biologics, biosimilars, or alternative mechanisms of action increase clinical complexity and healthcare costs while creating uncertainty regarding sustained treatment effectiveness. Consequently, physicians often adopt conservative treatment strategies, limiting rapid uptake of newer biologics and targeted therapies despite continued innovation in the rheumatoid arthritis market.
The increasing use of biologics and JAK inhibitors requires extensive long-term pharmacovigilance due to risks of serious infections, malignancies, major adverse cardiovascular events, and thromboembolic complications. Regulatory authorities mandate continuous post-marketing safety surveillance and periodic risk evaluations, increasing development and commercialization costs. These stringent safety monitoring requirements often delay physician adoption of newer therapies and limit their use in high-risk patient populations, restraining rheumatoid arthritis market expansion.
Expansion of Rheumatology Molecular Diagnostics and Rising Adoption of Subcutaneous Self-administration Platforms Offer Growth Opportunities to Market Players
The growing adoption of molecular diagnostics and companion biomarker testing is creating significant opportunities for rheumatoid arthritis therapy developers. Precision diagnostic platforms capable of identifying predictive biomarkers for biologic and targeted synthetic DMARD response are enabling more personalized treatment selection and improving clinical outcomes. In 2025, the American College of Rheumatology's RISE Registry expanded its real-world data capabilities by incorporating biomarker-linked clinical datasets, supporting precision treatment strategies and creating opportunities for manufacturers developing targeted therapies alongside companion diagnostic solutions.
The increasing shift toward subcutaneous self-administered biologics and wearable drug-delivery technologies is opening new opportunities across the rheumatoid arthritis market. Healthcare systems are promoting home-based treatment to reduce infusion center utilization and improve patient convenience. The US FDA approved multiple high-concentration citrate-free subcutaneous biologic formulations and autoinjector presentations for inflammatory diseases, enabling reduced administration frequency and improved adherence. This transition is encouraging pharmaceutical companies to invest in patient-centric delivery platforms, digital adherence solutions, and next-generation self-injection technologies that expand market penetration.
Declining Commercial Viability of Novel Biologics and Increasing Therapeutic Fragmentation Challenges Market Growth
The rapid expansion of biosimilars for TNF inhibitors, IL-6 inhibitors, and CD20-targeted biologics is reducing pricing power for innovator therapies and increasing competitive pressure on newly launched rheumatoid arthritis drugs. Manufacturers must demonstrate substantial clinical superiority over lower-cost biosimilars to achieve reimbursement and physician adoption. This compressed commercial window reduces return on R&D investment and discourages development of follow-on biologics targeting already crowded inflammatory pathways.
The rheumatoid arthritis treatment landscape is becoming increasingly fragmented with TNF inhibitors, IL-6 inhibitors, CTLA-4 modulators, B-cell therapies, JAK inhibitors, TYK2 inhibitors, and emerging immune-reset therapies competing for overlapping patient populations. This complexity makes optimal treatment sequencing difficult, limits clear differentiation for new entrants, and increases evidence requirements for comparative effectiveness. Manufacturers must generate extensive head-to-head and real-world clinical data to establish positioning, creating significant commercialization and market access challenges.
Request Customizationto receive a tailored report.
Based on drug type, the pharmaceuticals segment is expected to grow at a CAGR of 6.19% during the forecast period, owing to increasing utilization of conventional DMARDs, corticosteroids, and NSAIDs as first-line therapies, broad generic availability, and favorable reimbursement across healthcare systems. Rising early diagnosis and combination treatment strategies further sustain demand for pharmaceutical therapies throughout long-term rheumatoid arthritis management.
The biologics & biosimilars segment is expected to grow at a CAGR of around 6.75% during the forecast period due to expanding biosimilar commercialization, increasing adoption of high-efficacy targeted biologics, and greater physician preference for precision immunology therapies. Improved patient access through cost-competitive biosimilars and wider reimbursement coverage further accelerates segment growth.
In 2025, the prescription segment is projected to grow at a CAGR of 6.87% during the forecast period, owing to mandatory physician supervision for biologics and targeted therapies, expanding specialty rheumatology care, and increasing implementation of treat-to-target clinical guidelines. Regular disease activity monitoring and dose optimization continue strengthening prescription-based treatment demand.
The over-the-counter segment is expected to grow at a CAGR of 6.90% during the forecast period, driven by increasing use of OTC analgesics and topical pain relief products for adjunctive symptom management, growing self-care awareness, and expanding retail pharmacy accessibility. Rising preference for immediate pain relief alongside prescription therapies further supports segment expansion.
Speak to an Analystto discuss market opportunities.
North America: Market Dominance Led by Rapid Uptake of Biosimilars and Broad Insurance Coverage for Specialty Immunology Therapies
The North America rheumatoid arthritis market accounted for the largest regional share of 51.93% in 2025, driven by extensive specialty rheumatology networks, favorable reimbursement for advanced biologics and targeted therapies, and widespread implementation of treat-to-target disease management. The region also benefits from robust healthcare infrastructure and established specialty pharmacy services. According to the CDC, approximately 53.2 million US adults had doctor-diagnosed arthritis in 2025, supporting sustained demand for rheumatoid arthritis diagnosis, monitoring, and long-term treatment.
The US rheumatoid arthritis market was valued at USD 12.41 billion in 2025, driven by broad insurance coverage for specialty immunology therapies, rapid uptake of biosimilars, and an extensive network of board-certified rheumatologists. Strong integration of specialty pharmacies, electronic prior authorization systems, and value-based care models improves treatment accessibility, continuity of care, and long-term adherence. The country's advanced biologics manufacturing capabilities and early adoption of innovative immunology therapies continue to strengthen market growth.
The rheumatoid arthritis market in Canada was valued at USD 1.69 billion in 2025, supported by universal healthcare coverage, expanding provincial access to biologics and biosimilars, and coordinated arthritis management programs. Public reimbursement initiatives are improving patient access to advanced immunology therapies while encouraging cost-effective biosimilar adoption. According to the Canadian Institute for Health Information (CIHI), Canada's total health spending is projected to reach CAD 261.84 billion in 2025, supporting continued investment in chronic disease management, including rheumatoid arthritis care.
Asia Pacific: Fastest Growth Driven by Expanding Rheumatology Care Infrastructure and Increasing Availability of Rheumatology Specialists
The Asia Pacific rheumatoid arthritis market is expected to grow at a CAGR of 7.26% during the forecast period, showcasing the fastest regional growth. Growth is supported by expanding rheumatology care infrastructure, improving reimbursement for biologics and biosimilars, and increasing diagnosis of autoimmune diseases. Governments are strengthening specialty healthcare services while improving access to advanced immunology therapies through healthcare reforms. The region also benefits from expanding biosimilar manufacturing capabilities and rising investments in chronic disease management across developing healthcare systems.
The China rheumatoid arthritis market was valued at USD 1.50 billion in 2025, driven by rapid expansion of tertiary hospitals, increasing availability of rheumatology specialists, and implementation of the National Reimbursement Drug List (NRDL), which has improved patient access to biologics and targeted therapies. Growing domestic biosimilar manufacturing, expanding autoimmune disease awareness, and continued healthcare modernization are accelerating adoption of advanced rheumatoid arthritis treatments across urban and provincial healthcare institutions.
The India rheumatoid arthritis market was valued at USD 823.68 million in 2025, fueled by expanding access to affordable biosimilars, increasing establishment of dedicated rheumatology departments, and rising penetration of private multispecialty hospitals. Growing health insurance coverage, improved awareness of early diagnosis, and increasing availability of specialty pharmacies are enhancing access to long-term disease management. Expansion of domestic biologics manufacturing further supports sustainable growth of the rheumatoid arthritis market.
The Japan rheumatoid arthritis market was valued at USD 915.60 million in 2025, supported by an aging population, widespread adoption of treat-to-target management strategies, and high utilization of advanced biologics and targeted synthetic DMARDs. The country's well-established rheumatology practice, universal healthcare coverage, and strong pharmacovigilance framework enable early adoption of innovative therapies while supporting long-term disease monitoring and optimized treatment outcomes for rheumatoid arthritis patients.
Unlock Regional Insightsto access country-level data, & regional trends.
The rheumatoid arthritis market competitive landscape is highly consolidated, with competition led by global biopharmaceutical companies specializing in immunology, biologics, biosimilars, and targeted small-molecule therapies. Leading players compete through continuous pipeline innovation, lifecycle management of blockbuster therapies, expansion of biosimilar portfolios, and development of novel mechanisms of action. Companies are also strengthening real-world evidence generation, precision medicine capabilities, and patient support programs to enhance treatment adoption. The rheumatoid arthritis market ecosystem is shaped by evolving clinical guidelines, biosimilar competition, regulatory scrutiny, value-based reimbursement, and increasing demand for personalized, long-term disease management solutions.
May 2026: The FDA approved Accord BioPharma and Bio-Thera’s Immgolis and Immgolis Intri as the first interchangeable biosimilars to Simponi and Simponi Aria for rheumatoid arthritis
December 2025: Adaptive Biotechnologies signed immune receptor licensing agreements with Pfizer worth up to USD 890 million to support rheumatoid arthritis research and therapeutic discovery.
November 2025: Alvotech and Advanz Pharma received MHRA marketing authorizations for Gobivaz, a biosimilar to Simponi/golimumab, for rheumatoid arthritis and other inflammatory diseases.
October 2025: Artiva Biotherapeutics received FDA Fast Track Designation for AlloNK in refractory rheumatoid arthritis and prioritized RA as its lead indication.
September 2025: Alvotech received marketing approval in Japan for AVT05, a biosimilar to Simponi/golimumab, marking the first golimumab biosimilar approval in a major market.
Customize This Report to Match Your Strategic Objectives
Author's Details
Healthcare Lead
Debashree Bora is a Healthcare Lead with over 7 years of industry experience, specializing in Healthcare IT. She provides comprehensive market insights on digital health, electronic medical records, telehealth, and healthcare analytics. Debashree’s research supports organizations in adopting technology-driven healthcare solutions, improving patient care, and achieving operational efficiency in a rapidly transforming healthcare ecosystem.
We are featured on:
sales@straitsresearch.com